Enhanced drug delivery by a prodrug approach effectively relieves neuroinflammation in mice.
暂无分享,去创建一个
M. Hiltunen | S. Auriola | M. Lehtonen | T. Natunen | K. Huttunen | D. Potěšil | Aaro J. Jalkanen | Tetsuya Terasaki | P. Hruska | Ahmed B Montaser | Janita Kuiri
[1] Guo Ci Teo,et al. dia-PASEF data analysis using FragPipe and DIA-NN for deep proteomics of low sample amounts , 2022, Nature Communications.
[2] K. Huttunen,et al. Comparison of Experimental Strategies to Study l-Type Amino Acid Transporter 1 (LAT1) Utilization by Ligands , 2021, Molecules.
[3] M. Blanco,et al. Small molecule therapeutics for neuroinflammation-mediated neurodegenerative disorders. , 2021, RSC medicinal chemistry.
[4] J. Masdeu,et al. Neuroinflammation is highest in areas of disease progression in semantic dementia. , 2021, Brain : a journal of neurology.
[5] K. Huttunen,et al. Improved L-Type Amino Acid Transporter 1 (LAT1)-Mediated Delivery of Anti-Inflammatory Drugs into Astrocytes and Microglia with Reduced Prostaglandin Production. , 2021, International journal of pharmaceutics.
[6] Z. Zdráhal,et al. SP3 Protocol for Proteomic Plant Sample Preparation Prior LC-MS/MS , 2021, Frontiers in Plant Science.
[7] Nadezhda T. Doncheva,et al. The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets , 2020, Nucleic Acids Res..
[8] Peter S. Jones,et al. Neuroinflammation predicts disease progression in progressive supranuclear palsy , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.
[9] A. Emili,et al. Loss of G-Protein Pathway Suppressor 2 Promotes Tumor Growth Through Activation of AKT Signaling , 2021, Frontiers in Cell and Developmental Biology.
[10] S. Auriola,et al. L-Type Amino Acid Transporter 1 Enables the Efficient Brain Delivery of Small-Sized Prodrug across the Blood-Brain Barrier and into Human and Mouse Brain Parenchymal Cells. , 2020, ACS chemical neuroscience.
[11] R. Zaragozá. Transport of Amino Acids Across the Blood-Brain Barrier , 2020, Frontiers in Physiology.
[12] K. Huttunen,et al. Targeting of Perforin Inhibitor into the Brain Parenchyma Via a Prodrug Approach Can Decrease Oxidative Stress and Neuroinflammation and Improve Cell Survival , 2020, Molecular Neurobiology.
[13] I. Fyfe. Aspirin and ibuprofen could lower risk of LRRK2 Parkinson disease , 2020, Nature Reviews Neurology.
[14] M. Lekander,et al. Comparison of bacterial lipopolysaccharide-induced sickness behavior in rodents and humans: Relevance for symptoms of anxiety and depression , 2020, Neuroscience & Biobehavioral Reviews.
[15] H. Bramlett,et al. IC100: a novel anti-ASC monoclonal antibody improves functional outcomes in an animal model of multiple sclerosis , 2020, Journal of Neuroinflammation.
[16] J. Wiśniewski. Filter Aided Sample Preparation - A tutorial. , 2019, Analytica chimica acta.
[17] Christoph B. Messner,et al. DIA-NN: Neural networks and interference correction enable deep proteome coverage in high throughput , 2019, Nature Methods.
[18] Li Hai,et al. Ascorbic acid-modified brain-specific liposomes drug delivery system with "lock-in" function. , 2019, Chemistry and physics of lipids.
[19] M. Hiltunen,et al. l-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia , 2019, Scientific Reports.
[20] Martin Eisenacher,et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..
[21] N. Ip,et al. Targeting Neuroinflammation as a Therapeutic Strategy for Alzheimer's Disease: Mechanisms, Drug Candidates, and New Opportunities. , 2018, ACS chemical neuroscience.
[22] T. Natunen,et al. Extracellular prolyl oligopeptidase derived from activated microglia is a potential neuroprotection target , 2018, Basic & clinical pharmacology & toxicology.
[23] J. Koistinaho,et al. Alzheimer’s Disease Phenotype or Inflammatory Insult Does Not Alter Function of L-Type Amino Acid Transporter 1 in Mouse Blood-Brain Barrier and Primary Astrocytes , 2018, Pharmaceutical Research.
[24] T. Nishimura,et al. Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell Line , 2018, Pharmaceutical Research.
[25] Jürgen Cox,et al. A Network Module for the Perseus Software for Computational Proteomics Facilitates Proteome Interaction Graph Analysis , 2018, bioRxiv.
[26] K. Brouwer,et al. Disease‐Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium , 2018, Clinical pharmacology and therapeutics.
[27] Muzamil Saleem,et al. Low-dose NSAIDs reduce pain via macrophage targeted nanoemulsion delivery to neuroinflammation of the sciatic nerve in rat , 2018, Journal of Neuroimmunology.
[28] K. Hansen,et al. Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist. , 2017, Journal of medicinal chemistry.
[29] K. Suk,et al. Astrocytic Orosomucoid-2 Modulates Microglial Activation and Neuroinflammation , 2017, The Journal of Neuroscience.
[30] George T Grossberg,et al. Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics , 2017, Expert review of neurotherapeutics.
[31] J. Schuetz,et al. ABCB6, an ABC Transporter Impacting Drug Response and Disease , 2017, The AAPS Journal.
[32] J. Leppänen,et al. Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure , 2016, Neurochemical Research.
[33] J. A. Spicer,et al. A Selective and Slowly Reversible Inhibitor of l-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells. , 2016, Journal of medicinal chemistry.
[34] M. Sharman,et al. Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer's disease , 2016, Neurochemistry International.
[35] Vikas Kumar,et al. Low dose aspirin like analgesic and anti-inflammatory activities of mono-hydroxybenzoic acids in stressed rodents. , 2016, Life sciences.
[36] P. Bergold. Treatment of traumatic brain injury with anti-inflammatory drugs , 2016, Experimental Neurology.
[37] S. G. Patching. Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery , 2017, Molecular Neurobiology.
[38] Matthias Mann,et al. Parallel Accumulation-Serial Fragmentation (PASEF): Multiplying Sequencing Speed and Sensitivity by Synchronized Scans in a Trapped Ion Mobility Device. , 2015, Journal of proteome research.
[39] David L Waning,et al. Assessment of muscle mass and strength in mice. , 2015, BoneKEy reports.
[40] N. Vale. 3.1 Amino Acids and Peptides in Medicine: Old or New Drugs? , 2015 .
[41] Marco Y. Hein,et al. Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ * , 2014, Molecular & Cellular Proteomics.
[42] Vincenzo Pucci,et al. Standardized workflows for increasing efficiency and productivity in discovery stage bioanalysis. , 2013, Bioanalysis.
[43] K. Stejskal,et al. Suppression of peptide sample losses in autosampler vials. , 2013, Journal of proteome research.
[44] J. Leppänen,et al. Erratum to: Design, Synthesis and Brain Uptake of LAT1-Targeted Amino Acid Prodrugs of Dopamine , 2013, Pharmaceutical Research.
[45] Emma Lloyd Raven,et al. The regulatory role of heme in neurons. , 2011, Metallomics : integrated biometal science.
[46] J. Leppänen,et al. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery. , 2011, Molecular pharmaceutics.
[47] Takashi Suzuki,et al. Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors , 2011, Journal of neurochemistry.
[48] C. Kruse,et al. Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. , 2010, Brain : a journal of neurology.
[49] Y. Yeung,et al. Rapid Detergent Removal from Peptide Samples with Ethyl Acetate for Mass Spectrometry Analysis , 2010, Current protocols in protein science.
[50] M. Tansey,et al. Molecular Neurodegeneration BioMed Central Review , 2009 .
[51] E. Hirsch,et al. Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.
[52] C. Stichel,et al. Upregulation of cathepsin S in the aging and pathological nervous system of mice , 2008, Brain Research.
[53] C. DeCarli,et al. Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham study , 2007, BMC Medical Genetics.
[54] T. Terasaki,et al. Contribution of Carrier-Mediated Transport Systems to the Blood–Brain Barrier as a Supporting and Protecting Interface for the Brain; Importance for CNS Drug Discovery and Development , 2007, Pharmaceutical Research.
[55] E. Ling,et al. Microglial activation and its implications in the brain diseases. , 2007, Current medicinal chemistry.
[56] Q. Smith. Carrier-mediated transport to enhance drug delivery to brain , 2005 .
[57] T. Järvinen,et al. Inefficient central nervous system delivery limits the use of ibuprofen in neurodegenerative diseases. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[58] J. Couzin. Halt of Celebrex Study Threatens Drug's Future, Other Trials , 2004, Science.
[59] D. Selkoe,et al. The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer's disease and Down syndrome brain. An immunocytochemical study. , 1995, The American journal of pathology.